Bergamaschi, R., Capobianco , M. and Ravasio, R. 2024. Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy. AboutOpen. 11, 1 (Jun. 2024), 48–56. DOI:https://doi.org/10.33393/ao.2024.3078.